research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
Search
for
Sort by
Research
120-150 / 1000+ results research MP45-10 HISTOMORPHOMETRICAL EVALUATION OF THE CORPUS CAVERNOSUM OF HYPERTENSIVE RATS TREATED WITH 5-?-REDUCTASE INHIBITORS
SHH protein helps nerve regeneration in hypertensive rats.
research Direct Vasodilators and Sympatholytic Agents
Direct vasodilators and sympatholytic agents are still useful for certain conditions despite being less common due to side effects and newer drugs.
research Lower Urinary Tract Symptoms in the Elderly Male: Choosing Wisely
research Androgen antagonists in androgen target tissues
Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
research Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.
research Alpha Blocker and 5-Alpha Reductase Inhibitor Prescribing Habits among Urologists and Primary Care Physicians
Urologists prescribe newer medications more often than primary care physicians, who could benefit from more education on treatment options.
research Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5α-reductase type 1 and 2
New chemical compounds were made that effectively block an enzyme linked to prostate growth.
research The Effect of Perinatal Blockade of Androgen Receptors on the Expression of Hypothalamic Estrogen Receptor‐a and Sexual Motivation in Male Rats
Blocking androgen receptors early in life increases estrogen levels and reduces sexual motivation in male rats.
research When two plus two must not equal four
Regulatory challenges make developing combination therapies in urology difficult and costly.
research Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Dutasteride is more effective than finasteride in reducing urinary retention and surgery risks in people aged 65 and older.
research Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis
Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
research Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
research 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
research 5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection
5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.
research Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice
Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
research MP45-12 CHRONIC ADMINISTRATION OF A LIMK2 INHIBITOR IMPROVES CAVERNOSAL VENO-OCCLUSIVE DYSFUNCTION THROUGH SUPPRESSION OF CAVERNOSAL FIBROSIS IN A RAT MODEL OF ERECTILE DYSFUNCTION AFTER CAVERNOSAL NERVE INJURY
Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
research Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
research Activity of steroid 4 and derivatives 4a–4f as inhibitors of the enzyme 5α-reductase 1
Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
research Synthesis of mimics of steroid A ring as potential enzyme inhibitors
Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.
research Inhibition of rat α-reductases by finasteride: Evidence for isozyme differences in the mechanism of inhibition
Finasteride effectively blocks rat enzymes, but with varying methods and strength.
research Dutasteride for the treatment of benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
research Adenosine A2B receptor: A pathogenic factor and a therapeutic target for sensorineural hearing loss
Blocking adenosine A2B receptor may prevent or treat hearing loss.
research A(1-7) reduces pathologies associated with SLE in MRL-lpr mice
A(1-7) treatment reduces symptoms of lupus in mice.
research HP-01-004 Histomorphometrical Evaluation of The Corpus Cavernosum of Hypertensive Rats Treated with 5-Alpha-Reductase Inhibitors
5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
research Comparative Effect of Finasteride and Dutasteride on Chromogranin A Levels
Finasteride and dutasteride both increase chromogranin A levels similarly.
research Dutasteride/finasteride
research Pharmacological Role and Clinical Applications of 5α-Reductase Inhibitors-Review Article for Pharmacists and Healthcare Professionals
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
research Antihormonal properties of some new A-homo-B, 19-dinor steroids of the androstane series
New A-homo-B, 19-dinor steroids showed strong antiandrogenic activity without affecting the enzyme 5α-reductase or androgen receptor binding.